PDF factsheet
      Z

cholesterol lowering intervention in cardiovascular prevention for high risk patients with or without LDL cholesterol elevation, clinical trials results

atorvastatin versus placebo
ASCOT, 2003
atorvastatin 10mg/d
versus
placebo
hypertensive patients aged 40-79 years with at least three other cardiovascular risk factorsdouble blind
Follow-up duration: 3.3 years
UK et Scandinavie
ezetimibe versus niacin
ARBITER-HALTS 6, 2010
addition of ezetimibe (10 mg/daily) to statin therapy
versus
extended-release niacin 2000 mg/daily
patients at high risk for vascular disease but with LDL-cholesterol levels <100 mg/dL and moderately low HDL-cholesterol levels (<50 mg/dL)open
Follow-up duration: 14 months
pravastatin versus placebo
PMSG, 1993
pravastatin 20 mg once daily
versus
placebo
patients with hypercholesterolemia(serum total cholesterol concentrations of 5.2 to 7.8 mmol/liter) and > or = 2 additional risk factors for atherosclerotic coronary artery diseasedouble blind
Follow-up duration: 26 weeks
PROSPER, 2002
pravastatin 40mg daily
versus
placebo
men and women aged 70-82 years with a history of, or risk factors for, vascular diseasedouble blind
Follow-up duration: 3.2 years
Ecosse, Irelande, Pays bas
REGRESS, 1995
pravastatin 40 mg daily
versus
placebo
symptomatic men with normal to moderately elevated serum cholesterol levelsdouble blind
Follow-up duration: 2 years
Netherlands
pravastatin versus usual care
ALLHAT, 2002
NCT00000542
pravastatin 40mg/d
versus
usual care
aged 55 years or older, moderately hypercholesterolemic, hypertensive participants with at least 1 additional CHD risk factoropen
Follow-up duration: 4.8 years
USA, Puerto Rico, Canada
rosuvastatin versus placebo
JUPITER, 2008
NCT00239681
rosuvastatin 20 mg daily
versus
placebo
apparently healthy individuals with low LDL-cholesterol levels of less than 130 mg per deciliter but elevated C-reactive-protein (high-sensitivity C-reactive protein levels of 2.0 mg per liter or higher)double blind
Follow-up duration: median 1.9 year
26 countries
simvastatin versus placebo
HPS, 2002
simvastatin 40 mg/d
versus
placebo
adults (aged 40-80 years) with coronary disease, other occlusive arterial disease, or diabetedouble blind
Follow-up duration: 5 years
UK

  Options


in first

in second

  Filter